DoW Bone Marrow Failure, Investigator-Initiated Research Award
- Response deadline
- Nov 4, 2026 Due in 61 days
- Date posted
- Jun 17, 2026
- Source
- Open notice
Description
Summary: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in bone marrow (BMF) failure research and/or patient care. Investigator-Initiated Research Award (IIRA) applications may involve translational and clinical research including studies in preclinical models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, this award mechanism does not support clinical trials. IIRA applications may also support Investigational New Drug (IND)-enabling efforts such as lead compound characterization, and assessments of formulation and stability, absorption, distribution, metabolism and excretion, dose/response and toxicology. Distinctive Features: This funding mechanism allows for a partnering Principal Investigator (PI). Only the initiating PI will submit a pre-application, but both PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.
Classifications
- NAICS12.420
Documents (1)
- DownloadHT942526BMFRPIIRA_GG.pdfapplication/pdf611 KB
Contacts
- help@ebrap.org301-619-1139
Similar contracts
- DoW Breast Cancer, Clinical Research Extension AwardDue Nov 18, 2026
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Due Nov 18, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardDue Nov 4, 2026
- DoW Neurofibromatosis Synergistic Idea AwardDue Sep 22, 2026
- DoW Neurofibromatosis Investigator-Initiated Research AwardDue Sep 22, 2026
- DoW Neurofibromatosis Exploration-Hypothesis Development AwardDue Sep 22, 2026